000 03571cam a2200457 i 4500
999 _c200442828
_d61040
003 TR-AnTOB
005 20230417160913.0
008 150203s2014 cy a sb 000 0 eng d
020 _a9789963717064
035 _a(OCoLC)910948346
040 _aDNLM
_beng
_dDNLM
_d20200114
_dWaSeSS
_cTR-AnTOB
_erda
041 0 _aeng
042 _apcc
060 0 0 _aWH 170
096 _bWH170
_e.G853 2014
245 0 0 _aGuidelines for the management of transfusion dependent thalassaemia (TDT) /
_ceditors M.D. Cappellini, Cohen A., Porter J., Taher A., Viprakasit V.
250 _a3rd edition.
264 1 _aNicosia (CY) :
_bThalassaemia International Federation,
_c2014.
300 _a251 pages :
_billustrations ;
_c23 cm
_eCD-ROM (4 3/4 in.)
336 _2rdacontent
_atext
_btxt
337 _2rdamedia
_aunmediated
_bn
338 _2rdacarrier
_avolume
_bnc
500 _aTitle from Bookshelf entry page.
520 3 _aThe full costs of treating patients with inherited disorders of haemoglobin is extremely variable among countries depending on different health care systems, varying methods of obtaining blood, different practices in screening for blood pathogens and different costs of drugs and equipment. It is evident that all countries would benefit from the sharing of experience and expertise in order to harmonize and optimize the quality of treatment as much as possible. The need for management guidelines for Transfusion Dependent Thalassaemias (TDT) is clear. Throughout the past four years, six major TDT management guidelines became available for use by thalassaemia care givers (TIF, US, Canadian, UK, Italian and Australian Guidelines). A comparison among those guidelines has been recently published (Musallam KM et al. Acta Haematologica 2013). In light of a swiftly evolving evidence, the need for revisiting and updating TDT management recommendations remains crucial. More importantly, ensuring access to such guidelines and careful application and implementation should only help arriving at early diagnosis of morbidity to allow prompt and effective management. It would also allow early prediction of risk and would enable preventive measures to be set in place saving unnecessary health care costs. This updated third edition of the TIF guidelines will offer valuable information to all allied healthcare professionals involved in the treatment of patients with TDT. It includes updated information on new approaches for more effective, safe and less laborious treatment, and an overview of the progress achieved to date towards a total cure using methods such as gene therapy and stem cell transplantation.
588 _aDescription based on version viewed May 1, 2015.
590 _aThis freely accessible collection of books may include only specific chapters of some books.
650 1 2 _aThalassemia
_xtherapy
_0https://id.nlm.nih.gov/mesh/D013789Q000628.
650 2 2 _aThalassemia
_xcomplications
_0https://id.nlm.nih.gov/mesh/D013789Q000150.
650 2 2 _aBlood Transfusion
_0https://id.nlm.nih.gov/mesh/D001803.
650 2 2 _aInternationality
_0https://id.nlm.nih.gov/mesh/D038622.
655 0 _aElectronic books.
700 1 _aCappellini, Maria-Domenica
_9132039
700 1 _aCohen, Alan,
_d1946-
700 1 _aPorter, John
_c(Hematologist)
700 1 _aTaher, Ali.
700 1 _aViprakasit, Vip.
710 2 _aThalassaemia International Federation.
856 4 0 _uhttps://www.ncbi.nlm.nih.gov/books/NBK269382
_zConnect to online resource via NCBI Bookshelf - All users
942 _2NLM
_cBK